Stock Yearly Return 2018
Start date: 01/02/2018
End date: 12/31/2018
Start price/share: $335.00
End price/share: $61.50
Dividends collected/share: $0.00
Total return: -81.64%
SLS Average Annual Return: -82.09%
Starting investment: $10,000.00
Ending investment: $1,836.00
Years: 0.99


SLS average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare SLS average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Growth of $10,000.00
Without Dividends Reinvested Into SLS


Also see:
SLS stock yearly return 2019
SLS stock yearly return 2020
SLS YTD return
SLS average annual return 10 years
SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company focused on developing cancer immunotherapeutics for a range of cancer indications. Co.'s product candidates include galinpepimut-S (GPS) and nelipepimut-S (NPS). Co.'s primary product candidate, GPS, is a cancer immunotherapeutic agent that targets the Wilms tumor 1 protein, which is present in 20 or more cancer types. NPS is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 expressing cancers. GALE-301 and GALE-302 are cancer immunotherapies that target the E39 peptide derived from the folate binding protein. The SLS stock yearly return is shown above.

The yearly return on the SLS stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2018 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon.

One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the SLS annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes
Get Free SEC filing alerts for SLS:
SLS SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
SELLAS Life Sciences Group (SLS) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

SNDX Average Annual Return
SNGX Average Annual Return
SNNA Average Annual Return
SNOA Average Annual Return
SNSS Average Annual Return
SPNE Average Annual Return
SPPI Average Annual Return
SPRO Average Annual Return
SRDX Average Annual Return
SRNE Average Annual Return
More Healthcare companies »

 

SLS Stock Yearly Return 2018 | www.AverageAnnualReturn.com | Copyright © 2021 - 2021, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.